
You are here
Consultations
We conduct public consultations as part of our broader stakeholder engagement work, including on changes to regulatory requirements or practices, reviews of business processes, standards or guidelines, and TGA fees and charges.
Filters
Status
Categories
- Advertising (2) Apply Advertising filter
- Australian Register of Therapeutic Goods (ARTG) (1) Apply Australian Register of Therapeutic Goods (ARTG) filter
- Biologicals (2) Apply Biologicals filter
- Remove Blood and blood components filter Blood and blood components (0)
- Remove Complementary medicines filter Complementary medicines (7)
- Fees/Payments (1) Apply Fees/Payments filter
- Remove Import/Export filter Import/Export (1)
- Labelling/Packaging (1) Apply Labelling/Packaging filter
- Legislation (3) Apply Legislation filter
- Listed medicines (2) Apply Listed medicines filter
- Medical devices/IVDs (55) Apply Medical devices/IVDs filter
- Medical devices safety (1) Apply Medical devices safety filter
- Medicines (2) Apply Medicines filter
- Medicines safety (1) Apply Medicines safety filter
- Remove OTC medicines filter OTC medicines (12)
- Remove Other therapeutic goods filter Other therapeutic goods (1)
- Prescription medicines (5) Apply Prescription medicines filter
- Scheduling (55) Apply Scheduling filter
- Therapeutic Goods Administration (TGA) (2) Apply Therapeutic Goods Administration (TGA) filter
- Remove Therapeutic goods regulation filter Therapeutic goods regulation (2)
- (-) Remove OTC medicines filter OTC medicines
- (-) Remove Import/Export filter Import/Export
- (-) Remove Blood and blood components filter Blood and blood components
- (-) Remove Therapeutic goods regulation filter Therapeutic goods regulation
- (-) Remove Other therapeutic goods filter Other therapeutic goods
- (-) Remove Complementary medicines filter Complementary medicines
Proposed update to the evidence guidelines for listed medicines
Closed on 1 April 2022
Proposed changes to Required Advisory Statements for Medicine Labels (RASML): Triptans
Closed on 17 September 2021
Proposed changes to Required Advisory Statements for Medicine Labels (RASML): Mometasone
Closed on 17 September 2021
Proposed minor changes to Required Advisory Statements for Medicine Labels (RASML): Chlorhexidine, hydrocortisone, ibuprofen
Closed on 17 September 2021
Proposed changes to Required Advisory Statements for Medicine Labels (RASML): Melatonin
Closed on 17 September 2021
Proposed changes to Required Advisory Statements for Medicine Labels (RASML): Methyl salicylate
Closed on 18 May 2021
Proposed changes to Required Advisory Statements for Medicine Labels (RASML): Lidocaine (lignocaine)
Closed on 18 May 2021
Proposed changes to Required Advisory Statements for Medicine Labels (RASML): Sedating antihistamines
Closed on 18 May 2021
Proposed changes to Required Advisory Statements for Medicine Labels (RASML): Menthol
Closed on 18 May 2021
Proposal for clarifying regulatory requirements for residual claims for disinfectants
Closed on 26 March 2021